Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: A single-centre randomized study

Journal of Viral Hepatitis

Volumn 13, Issue 9, 2006, Pages 597-604

  Yuan, J ^a,b   Lin, J ^b   Xu, A ^b   Li, H ^b   Hu, B ^b   Chen, J ^b   Yao, J ^a   Dong, H ^a   Jiang, M ^a  

^a WUHAN UNIVERSITY   (China)

^b HUIZHOU MUNICIPAL CENTRAL HOSPITAL   (China)

Author keywords

Hepatitis B immunoglobulin; Hepatitis B virus; Perinatal; Pregnancy; Prevention; Transmission

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; ADULT; ANTIGEN DETECTION; ARTICLE; BIRTH; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GESTATION PERIOD; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LABOR; MAJOR CLINICAL STUDY; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 33747195261     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00738.x     Document Type: Article

References (27)

1. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683.
3. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-2838.
4. Karayiannis P, Main J, Thomas HC. Hepatitis vaccines. Br Med Bull 2004; 70: 29-49.
5. del Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630.
6. Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther 2004; 2: 133-145.
7. Karayiannis P. Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004; 2: 745-760.
8. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1: 232-241.
9. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51: 761-785.
10. Zhu Q, Lu Q, Gu X et al. A preliminary study on interruption of hepatitis B intrauterine transmission. Chin J Pediatr (Chin) 1995; 33: 93-94.
11. Zhu Q, Lu Q, Gu X et al. A preliminary study on interruption of HBV transmission in uterus. Chin Med J (Engl) 1997; 110: 145-147.
12. Yue Y, Yang X, Zhang S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism. Chin Med J (Engl) 1999; 112: 37-39.
13. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003; 9: 1501-1503.
14. Li XM, Shi MF, Yang YB et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004; 10: 3215-3217.
15. Zhu Q, Yu G, Yu H et al. A randomized control trial on interruption of HBV transmission in uterus. Chin Med J (Engl) 2003; 116: 685-687.
16. Kong F, Yu H, Ba A, Zhang T, Wang Y. Clinical observation on the interruption of intrauterine transmission of HBV by HBIg. J Med Theory Pract (Chin) 1999; 15: 319.
17. Guo M, Guo F, Pan Z, Ma X, Chen F, Meng W. Interruption of mother to child transmission of HBV by HBIg and hepatitis B vaccine. Suzhou University J Med Sci (Chin) 2004; 24: 773-774.
18. Li C. Clinical observation on interruption of intrauterine transmission of HBV by HBIG. Chin J Clin Hepatol (Chin) 2004; 20: 196.
19. Li H, Sun Y. Investigation on interrupting mother to child transmission of HBV by HBIg and hepatitis B vaccine. Occup Health (Chin) 2005; 21: 120.
20. van Nunen AB, de Man RA, Heijtink RA, Vossen AC, Schalm SW. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepat 2002; 9: 221-228.
21. Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes. J Med Virol 2001; 64: 427-434.
22. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Vimolkej L, Yano M. Is there evidence for intrauterine HBV infection in newborns of hepatitis B carrier mothers? Southeast Asian J Trop Med Public Health 1997; 28: 365-369.
23. Rumi MA, Begum K, Hassan MS et al. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery: implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998; 59: 318-322.
24. Moodley D, Moodley J, Coovadia H et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735.
25. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002; 359(9316): 1488-1489.
26. Van Zonneveld M, Van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297.
27. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32: 1040-1041.